ID: h-308757f973
Hypothesis
Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-first or ENS-first mechanism rather than direct brain exposure
Low-micromolar systemic SCFA exposure is unlikely to directly drive substantia nigra alpha-synuclein clearance, but colon and enteric nervous system compartments experience much higher local exposure and may show reduced pS129-alpha-syn,.
EvidencePending (0%)📖 7 cit🗣 1 debates✓ 7 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Low-micromolar systemic SCFA exposure is unlikely to directly drive substantia nigra alpha-synuclein clearance, but colon and enteric nervous system compartments experience much higher local exposure and may show reduced pS129-alpha-syn, lower seeding pressure, and delayed gut-to-brain propagation. This is the strongest translationally credible hypothesis because it matches exposure reality and explains why dietary or microbiome interventions could matter without requiring pharmacologic brain concentrations.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["SNCA Alpha-Synuclein<br/>Presynaptic Protein"]
B["SNCA Misfolding<br/>Environmental Stress"]
C["SNCA Oligomers<br/>Toxic Protofibrils"]
D["Mitochondrial Pore<br/>Membrane Disruption"]
E["Lewy Body Formation<br/>Cytoplasmic Inclusions"]
F["Dopaminergic Neuron<br/>Dysfunction/Death"]
G["Nigrostriatal Degeneration<br/>Motor Symptoms"]
H["SNCA A53T/A30P/E46K<br/>Familial PD Mutations"]
A --> B
B --> C
C --> D
C --> E
D --> F
E --> F
F --> G
H -.->|"accelerates"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8⚖️ Evidence
⚖️ Evidence Matrix7 supports2 contradicts
Supports
Human circulating SCFAs are low, supporting the idea that any physiologic effect is more likely to occur in gut or ENS compartments than through direct CNS exposure.
Supports
Sodium butyrate reduced colonic and nigral alpha-syn pathology in a rotenone model, consistent with a possible gut-origin effect even though dosing was pharmacologic.
Supports
R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation.
Supports
Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy.
Supports
MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease.
Supports
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
Supports
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
Contradicts
Existing studies do not establish a temporal gut-first sequence or direct aggregate clearance kinetics under physiologic exposure.
Contradicts
Low plasma SCFA measurements support exposure skepticism but do not themselves prove gut-first causality.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SNCA
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for SNCA from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SNCA.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.8%
Volatility
Low
0.0040
Events (7d)
3
Price History
▼13.0%💾 Resource Usage
LLM Tokens
19,114
$0.0573
Total Cost
$0.0573
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF SNCA transgenic mice receive equivalent-dose SCFA supplementation via oral gavage versus intracerebroventricular (ICV) minipump infusion for 8 weeks, THEN oral but not ICV-administered SCFA will re | Oral SCFA group: colon pS129-alpha-syn reduced by ≥40% (vs. vehicle); ICV SCFA group: colon pS129-alpha-syn reduced by ≤15% (vs. vehicle), with no significant d | — no observation — | pending | 0.55 |
| IF germ-free mice colonized with human gut microbiota receive oral SCFA supplementation (sodium propionate, butyrate, and acetate at 10-40 mM in drinking water for 8 weeks), THEN colonic pS129-alpha-s | Colonic pS129-alpha-syn reduced by ≥30% at week 4-6; substantia nigra pS129-alpha-syn reduced by ≤10% at week 6 | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF germ-free mice colonized with human gut microbiota receive oral SCFA supplementation (sodium propionate, butyrate, and acetate at 10-40 mM in drinking water for 8 weeks), THEN colonic pS129-alpha-syn levels will be significantly reduced (≥30% decrease by ELISA or MSD) BEFORE substantia nigra pS12
Predicted outcome: Colonic pS129-alpha-syn reduced by ≥30% at week 4-6; substantia nigra pS129-alpha-syn reduced by ≤10% at week 6
Falsification: Substantia nigra pS129-alpha-syn reduces by ≥30% at the same timepoint as colonic reduction (week 4) or before colonic reduction is detectable, indicating SCFA can act directly on the brain independen
pendingconf 55%
IF SNCA transgenic mice receive equivalent-dose SCFA supplementation via oral gavage versus intracerebroventricular (ICV) minipump infusion for 8 weeks, THEN oral but not ICV-administered SCFA will reduce colon pS129-alpha-syn burden, demonstrating that pharmacologic brain concentrations alone are i
Predicted outcome: Oral SCFA group: colon pS129-alpha-syn reduced by ≥40% (vs. vehicle); ICV SCFA group: colon pS129-alpha-syn reduced by ≤15% (vs. vehicle), with no sig
Falsification: ICV SCFA administration reduces colon pS129-alpha-syn by ≥40% (equivalent to oral), indicating SCFAs can act systemically through the bloodstream or that direct brain exposure is sufficient to drive g
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.